Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.

@article{Satoh2004EnhancedST,
  title={Enhanced systemic T-cell activation after in situ gene therapy with radiotherapy in prostate cancer patients.},
  author={Takefumi Satoh and Bin S. Teh and Terry L. Timme and W Mai and Yehoshua Gdor and Nobuyuki Kusaka and Tetsuo Fujita and Christina K Pramudji and Maria T. Vlachaki and Gustavo Ayala and Thomas M. Wheeler and Robert J. Amato and Brian J. Miles and Dov Kadmon and Edward Brian Butler and Timothy C Thompson},
  journal={International journal of radiation oncology, biology, physics},
  year={2004},
  volume={59 2},
  pages={562-71}
}
PURPOSE In situ cytotoxic gene therapy can potentially trigger a systemic immune response, which could impact occult metastatic disease. We are currently conducting three clinical trials using in situ adenoviral vector mediated herpes simplex virus-thymidine kinase (HSV-tk) gene delivery followed by the HSV-tk prodrug ganciclovir (GCV) or valacyclovir (VCV… CONTINUE READING